In a report issued on July 9, Andrew D’silva from B.Riley FBR reiterated a Buy rating on OptimizeRx Corporation (Other OTC: OPRX), with a price target of $15. The company’s shares closed yesterday at $10.60, close to its 52-week high of $11.24.
According to TipRanks.com, D’silva is a 5-star analyst with an average return of 26.4% and a 60.9% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Cytori Therapeutics Inc, and Sorrento Therapeutics.
OptimizeRx Corporation has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Based on OptimizeRx Corporation’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $189.2K. In comparison, last year the company had a GAAP net loss of $361.5K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records (EHR), which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. Its services include EHR workflow solutions such as financial messaging, patient education, and brand messaging; and brand support.
